Publications and Clinical Trials.

Please find links below to explore the results of our latest trials and publications.

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Slade, M., Khaled, A., Fiala, M., McDonald, Z., Liyasova, M., Fortier, J., Zaydman, M., Kelley, S., Crees, Z. D., Schroeder, M. A., Stockerl-Goldstein, K., Yang, L., & Vij, R. (2023). In Oral and Poster Abstracts, Session 652. Multiple Myeloma: Clinical and Epidemiological: Poster II. Presented at the American Society of Hematology Annual Meeting, December 10, 2023.

This study explores the utility of a EasyM for monitoring measurable residual disease (MRD) in multiple myeloma (MM) patients. The research findings indicate that MRD status determined by EasyM is a strong predictor of progression-free survival (PFS) after AHCT, with different cutoffs for IgG and IgA/LC myeloma patients, emphasizing the potential clinical significance of this approach for tailored therapy and prognosis assessment in MM. 95 patients, retrospective.

Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

Zhao, J., Khong, T. T., Gorniak, M., Khaled, A., McDonald, Z., Reynolds, J., Wong, D., Bingham, N., Johnston, A. M., Motorna, O., Murphy, N. E., Quach, H., Yang, L., & Spencer, A. (2023). In Oral and Poster Abstracts, Session 652. Multiple Myeloma: Clinical and Epidemiological: Poster II. Presented at the American Society of Hematology Annual Meeting, December 10, 2023.

In this study, we have evaluated EasyM in MM patients undergoing sequential NGF (EuroFlow platform) MRD assessment. EasyM is demonstrated to be more sensitive than NGF, and detected patients with rising M-protein levels before relapse. 43 patients, retrospective.

Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias.

Liyasova, M., Slade, M., Fortier, J., Vij, R., Fiala, M., Yang, L., & Ma, B. (2023). In Oral and Poster Abstracts, Session 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I. Presented at the American Society of Hematology Annual Meeting, December 9, 2023.

Dimerite is a novel mass spectrometry-based assay for the detection and quantification of Free Light Chain (FLC) dimers in the serum of patients with plasma cell dyscrasias. The assay showed excellent linearity and correlation with the standard Freelite assay, demonstrating its potential as a diagnostic and monitoring tool for conditions like light chain multiple myeloma (LC MM). This technology is related to EasyM but is not part of the EasyM assay. Dimerite is still in development and further clinical studies are sought.

Clonotypic Mass Spectrometry with EasyM Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, , Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang and Ravi Vij. American Society of Hematology Annual Meeting and Expo 2023, Poster 1908, Session 652

Retrospective, blinded clinical study. EasyM™ compared against SPEP and ClonoSEQ® NGS in 19 patients with MM.

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)

Mariya Liyasova, Zac McDonald, Paul Taylor; Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G. Atenafu, Giovanni Piza; Bin Ma; Donna Reece; Suzanne Trudel Clin Cancer Res (2021) 27 (18):5028–5037.

Phase 2 clinical study: M-protein monitoring and relapse detection in 26 patients who achieved complete response (CR). EasyM™ results compared vs SPEP and MFC 10-4

Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients

Zac McDonald, Paul Taylor, Mariya Liyasova, Qixin Liu, and Bin Ma, Journal of Proteome Research 2021 20 (8), 4176-4185,

Application of EasyM™ in a real-world setting.


Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring
May 14, 2024

A Canadian Multiple Myeloma (MM) clinical trial sponsored by Rapid Novor, has enrolled its first patient. This is the first Canadian prospective clinical study aiming to evaluate the EasyM™ assay (mass spectrometry measurement of a myeloma biomarker) for disease response in newly diagnosed MM patients (NDMM) receiving standard of care treatment.

EasyM, blood test for residual myeloma activity, certified in US
March 20, 2023

The EasyM™ assay has been granted Clinical Laboratory and Improvement Amendments (CLIA) certification from U.S. regulatory authorities.  Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual disease.